Integrate analysis of bulk and single-cell RNA sequencing demonstrates a transcriptional pattern characterized by GDF15 of tumor cells that predicts immunotherapy efficacy in non-small cell lung cancer DOI Creative Commons
Xianfei Zhang, Z. S. Yin, Xueyu Chen

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 18, 2024

Abstract The advent of immunotherapy has transformed the landscape lung cancer treatment. Nevertheless, question which populations may benefit from this approach remains unsolved. In study, we designed a pipeline based on machine learning for processing RNA-sequencing data patients treated with immune check point blockade therapy to identify most important genes that predict prognosis. final model was developed by accelerated oblique random forests (AORSF) its best performance training, test and 10-cross validation set. An intriguing phenomenon revealed single-cell RNA sequencing prognostically unfavorable were predominantly expressed specific tumor cell characterized GDF15, while CXCL9-positive macrophages favorable genes. highest score genes, as calculated AUCell package, not only exhibited feature epithelial migration but also possessed transcription factor indicating proliferation potency differentiation. Furthermore, higher level expression GDF15 proportion can both worse overall survival in an external melanoma cohort checkpoint therapy. conclusion, our study identified hub affect efficacy represent target improving outcomes patients.

Language: Английский

Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model DOI Creative Commons
Gang Fang,

Zhipeng Pi,

Yu An

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 24, 2025

Background and objectives Both gumarontinib savolitinib have demonstrated efficacy in treating non-small-cell lung cancer (NSCLC) with tumors harboring mesenchymal–epithelial transition factor gene exon 14 (METex14) skipping. However, the comparison of their pharmacoeconomics profiles remains limited. This study aims to evaluate cost-effectiveness versus for treatment METex14 skipping NSCLC China. Methods A 3-state partitioned survival model (PSM) was developed lifetime horizon from perspective Chinese healthcare system. Survival inputs were based on an unanchored matching-adjusted indirect using individual patient data GLORY trial adjust characteristics NCT02897479. Costs outcomes discounted at annual rate 5%. Sensitivity scenario analyses conducted explore uncertainty. Results Gumarontinib gained additional 0.10 QALYs incremental cost $1,893 compared savolitinib, resulting ICERs $19,243/QALY, which is below threshold 3 times GDP per capita China ($35,007 2022). confirmed robustness base-case results. Conclusion a cost-effective option

Language: Английский

Citations

0
The Exploration of the Comprehensive and Advanced Training Transformation Model for New Engineering Graduate Students DOI Open Access
Xin Zhao, Y.N. Zan, Yu Liu

et al.

Open Journal of Social Sciences, Journal Year: 2025, Volume and Issue: 13(01), P. 374 - 382

Published: Jan. 1, 2025

Language: Английский

Citations

0
Clinical characteristics and survival outcomes of long-term responders for advanced nonsmall cell lung cancer patients with first-line PD-1/PD-L1 inhibitors: a multicenter retrospective study DOI

Zhijuan Du,

Xiangwei Ge,

Li Yao

et al.

Postgraduate Medical Journal, Journal Year: 2025, Volume and Issue: unknown

Published: April 19, 2025

Abstract Background Immunotherapy has shown long-term benefits in advanced nonsmall cell lung cancer patients. However, the clinical characteristics, prognosis, and selection of appropriate therapies for responders (LTR) to first-line programmed death protein-1/programmed ligand-1 (PD-L1) inhibitors remain undetermined. Methods About 413 patients were included from 1 June 2015 31 August 2021. It examined clinicopathologic data, overall survival distributions, treatment strategies involving immune checkpoint inhibitors. Results Among patients, 213 (51.6%) LTRs. PD-L1 expression ≥50% was observed 39.1% LTR higher than non-LTR (21.7%). After propensity score matching, Cox univariable analysis revealed pathological type (hazard ratio [HR] 0.563; 95% confidence interval [CI]: 0.391–0.811; P = .002), bone metastasis (HR 1.820; CI: 1.278–2.590; .001), liver 2.220; 1.291–3.817; .004) as significant predictors LTR. The 0.641; 0.441–0.932; .020), 1.593; 1.106–2.293; .012), 1.046–3.165; .034) multivariable analysis. Significant difference showed (P < .0001) Pembrolizumab-chemotherapy squamous carcinoma group compared with Sintilimab-chemotherapy. Conclusions Nonsquamous carcinoma, metastasis, a proportion expression. Compared Sintilimab-chemotherapy, may be more promising Key messages What is already known on this topic — (IO) demonstrated (NSCLC). optimal unclear, necessitating further investigation. study adds This identifies nonsquamous absence NSCLC exhibit (≥50%). Additionally, shows superior outcomes How might affect research, practice, or policy These findings provide critical insights patient stratification therapy optimization NSCLC. identification predictive factors therapeutic combinations can guide decision-making, personalized strategies, inform future research IO

Language: Английский

Citations

0
Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China DOI Creative Commons

Xiaoyu Zhang,

Xiongxiong Fan,

Jin Zhang

et al.

Frontiers in Public Health, Journal Year: 2024, Volume and Issue: 12

Published: July 18, 2024

Background Tislelizumab is the first PD-1 inhibitor in China to demonstrate superior efficacy second-line or third-line treatment of patients with advanced metastatic non-small-cell lung cancer (NSCLC). This study aimed evaluate cost-effectiveness tislelizumab compared docetaxel from a Chinese healthcare system perspective. Methods A dynamic Markov model was developed comparison second treatment. The data utilized were derived RATIONALE-303 clinical trial, while cost and utility values obtained drug service platform published studies. primary outcomes encompassed quality-adjusted life years (QALYs), costs, incremental ratios (ICERs). One-way sensitivity analysis probabilistic conducted validate robustness base case results. Results group demonstrated increase CNY 117,473 gain 0.58 QALYs group, resulting an ICER value 202,927 per QALY gained. Conclusion administration NSCLC not only extends progression-free survival (PFS) overall (OS). Moreover, this demonstrates favorable profile across population.

Language: Английский

Citations

2
Comparison of the efficacy and safety of domestically produced tislelizumab, camrelizumab, and imported pembrolizumab in the treatment of advanced NSCLC: a real-world retrospective study DOI
Jia Hu,

MengTing Li,

Zeyu Xie

et al.

Clinical & Translational Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: June 27, 2024

Language: Английский

Citations

1
Efficacy and safety of camrelizumab-based comprehensive treatment for non-small cell lung cancer: a systematic review and meta-analysis DOI Creative Commons

Nuerbiyamu Maimaitiyiming,

Yue Li, Yun‐Feng Cao

et al.

Therapeutic Advances in Medical Oncology, Journal Year: 2024, Volume and Issue: 16

Published: Jan. 1, 2024

Background: Many studies show that camrelizumab combination therapy can significantly improve progression-free survival (PFS) and overall (OS) in non-small cell lung cancer (NSCLC). However, the time of to market is short, there no systematic evaluation camrelizumab-based comprehensive treatment NSCLC. Objectives: To systematically evaluate efficacy safety comprehensively treating Design: A review meta-analysis. Data sources methods: Databases, including PubMed, Web Science, Embase, Cochrane, were searched by computer before August 2023 based on Preferred Reporting Items for Systematic Review Meta-Analysis (PRISMA) guidelines, reports NSCLC collected, RevMan 5.4 software was employed meta-analysis finally. Results: Totally, 5 RCTs, 2 cohort studies, 12 single-arm included. The results revealed that, compared with without camrelizumab, considerably extended OS (hazard ratio (HR) = 0.60, 95% confidence interval (CI): (0.44–0.82), p < 0.01), PFS (HR 0.42, CI: (0.28–0.63), event-free (EFS) 0.55, (0.44–0.68), 0.01). median objective response rate 41% (95% 28%–53%), disease control 84% 78%–89%). Furthermore, terms occurrence grades 3–5 adverse events, incidence neutropenia lower group than group, while leukopenia rash higher significant difference other events. Among events did not exceed 10%. Conclusion: Treatment combined effectively prolong OS, PFS, EFS patients good safety, chemotherapy an effective option patients.

Language: Английский

Citations

1
Integrate analysis of bulk and single-cell RNA sequencing demonstrates a transcriptional pattern characterized by GDF15 of tumor cells that predicts immunotherapy efficacy in non-small cell lung cancer DOI Creative Commons
Xianfei Zhang, Z. S. Yin, Xueyu Chen

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 18, 2024

Abstract The advent of immunotherapy has transformed the landscape lung cancer treatment. Nevertheless, question which populations may benefit from this approach remains unsolved. In study, we designed a pipeline based on machine learning for processing RNA-sequencing data patients treated with immune check point blockade therapy to identify most important genes that predict prognosis. final model was developed by accelerated oblique random forests (AORSF) its best performance training, test and 10-cross validation set. An intriguing phenomenon revealed single-cell RNA sequencing prognostically unfavorable were predominantly expressed specific tumor cell characterized GDF15, while CXCL9-positive macrophages favorable genes. highest score genes, as calculated AUCell package, not only exhibited feature epithelial migration but also possessed transcription factor indicating proliferation potency differentiation. Furthermore, higher level expression GDF15 proportion can both worse overall survival in an external melanoma cohort checkpoint therapy. conclusion, our study identified hub affect efficacy represent target improving outcomes patients.

Language: Английский

Citations

0